CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biomx Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biomx Inc
850 New Burton Road, Suite 201
Phone: +972 723942377p:+972 723942377 DOVER, DE  19904  United States Ticker: PHGEPHGE
Business Summary
BiomX Inc. is a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI. Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and creating novel phage using synthetic biology, it develops phage-based therapies intended to address large-market diseases. The Company offers two phage-based product types: Fixed cocktail therapy and Personalized therapy. Its ongoing programs include BX011 and BX211. BX011 is a fixed multi-phage cocktail, for the treatment of DFI associated with Staphylococcus aureus (S. aureus). BX211 is a phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO) associated with S. aureus.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes---

Industries
SIC Code Description
6726 Unit investment trusts, face-amount certificate offices
6770 Blank checks
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer MichaelOster 54 3/4/2026 3/4/2026
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer DavidRokach 58 2/25/2026 2/25/2026
Independent Director GuyArieli 43 2/25/2026 2/25/2026
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Adaptive Phage Therapeutics, Inc. 708 Quince Orchard Road, Suite 205 Gaithersburg MD United States

Business Names
Business Name
Adaptive Phage Therapeutics, Inc.
Adaptive Phage Therapeutics, LLC
CHAC U
PHGE
PHGE U
Zorronet Ltd

General Information
Number of Employees: 20 (As of 12/31/2025)
Outstanding Shares: 6,543,516 (As of 3/23/2026)
Shareholders: 72
Stock Exchange: ASE
Fax Number: (302) 734-1476


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 11, 2026